Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Masters of Immunology

  • Masters of Immunology
    The Immunological Synapse
    Michael L. Dustin
    Cancer Immunol Res November 1 2014 2 (11) 1023-1033; DOI:10.1158/2326-6066.CIR-14-0161

Cancer Immunology at the Crossroads: Public/Private Partnership

  • Cancer Immunology at the Crossroads: Public/Private Partnership
    Prostate Cancer Immunotherapy: Beyond Immunity to Curability
    Jonathan W. Simons
    Cancer Immunol Res November 1 2014 2 (11) 1034-1043; DOI:10.1158/2326-6066.CIR-14-0174

Priority Brief

  • Priority Brief
    BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma
    Shannon M. Steinberg, Peisheng Zhang, Brian T. Malik, Andrea Boni, Tamer B. Shabaneh, Katelyn T. Byrne, David W. Mullins, Constance E. Brinckerhoff, Marc S. Ernstoff, Marcus W. Bosenberg and Mary Jo Turk
    Cancer Immunol Res November 1 2014 2 (11) 1044-1050; DOI:10.1158/2326-6066.CIR-14-0074

    Steinberg and colleagues show that the BRAF-inhibitor PLX4720 enhanced intratumoral Treg apoptosis and decreased both the proportion and the per-cell immunosuppressive function of MDSCs, thus informing the design of combinatorial therapies for melanoma.

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
    David L. Bajor, Xiaowei Xu, Drew A. Torigian, Rosemarie Mick, Laura R. Garcia, Lee P. Richman, Cindy Desmarais, Katherine L. Nathanson, Lynn M. Schuchter, Michael Kalos and Robert H. Vonderheide
    Cancer Immunol Res November 1 2014 2 (11) 1051-1058; DOI:10.1158/2326-6066.CIR-14-0154

    Bajor and colleagues used next-generation sequencing of TCRs in the tumor and blood to identify the emergence and persistence of a de novo T-cell repertoire following agonistic CD40 therapy, highlighting the potential of immune agonists in therapy and TCR deep sequencing in immune assessment.

Research Articles

  • Research Articles | AuthorChoice
    Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma
    Nathan Singh, Xiaojun Liu, Jessica Hulitt, Shuguang Jiang, Carl H. June, Stephan A. Grupp, David M. Barrett and Yangbing Zhao
    Cancer Immunol Res November 1 2014 2 (11) 1059-1070; DOI:10.1158/2326-6066.CIR-14-0051

    Singh and colleagues show that RNA-CAR T cells mediate rapid and long-term tumor destruction when delivered locally but not when delivered systemically due to the inability of RNA-CAR T cells to penetrate the tumor microenvironment.

  • Research Articles
    Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma
    Kelly G. Paulson, Andrew Tegeder, Christoph Willmes, Jayasri G. Iyer, Olga K. Afanasiev, David Schrama, Shinichi Koba, Renee Thibodeau, Kotaro Nagase, William T. Simonson, Aaron Seo, David M. Koelle, Margaret Madeleine, Shailender Bhatia, Hideki Nakajima, Shigetoshi Sano, James S. Hardwick, Mary L. Disis, Michele A. Cleary, Jürgen C. Becker and Paul Nghiem
    Cancer Immunol Res November 1 2014 2 (11) 1071-1079; DOI:10.1158/2326-6066.CIR-14-0005

    Paulson and colleagues report that 84% of Merkel cell carcinoma (MCC) tumors downregulated MHC-I expression, and MCC patients treated with intralesional IFNs had increased MHC-I expression on their tumor cells, thus promoting the use of immune-stimulating therapies for MCC.

  • Research Articles | AuthorChoice
    Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway
    Rasha Abu-Eid, Raed N. Samara, Laurent Ozbun, Maher Y. Abdalla, Jay A. Berzofsky, Kevin M. Friedman, Mikayel Mkrtichyan and Samir N. Khleif
    Cancer Immunol Res November 1 2014 2 (11) 1080-1089; DOI:10.1158/2326-6066.CIR-14-0095

    Abu-Eid, Samara, and colleagues used PI3K–Akt pathway inhibitors to selectively disrupt homeostasis of immunosuppressive Tregs in naïve and tumor-bearing mice, and to enhance vaccine-induced antitumor immune responses, highlighting the therapeutic potential of these inhibitors as Treg-depleting reagents.

  • Research Articles
    Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
    Benedetto Farsaci, Renee N. Donahue, Michael A. Coplin, Italia Grenga, Lauren M. Lepone, Alfredo A. Molinolo and James W. Hodge
    Cancer Immunol Res November 1 2014 2 (11) 1090-1102; DOI:10.1158/2326-6066.CIR-14-0076

    Farsaci, Donahue, and colleagues show that combining antiangiogenic tyrosine kinase inhibitors with vaccines increased tumor-infiltrating lymphocytes, decreased tumor density, and enhanced tumor oxygenation, indicating the potential of altering tumor architecture in cancer therapy.

  • Research Articles
    IL4 Limits the Efficacy of Tumor-Targeted Antibody Therapy in a Murine Model
    Rishi Surana, Shangzi Wang, Wei Xu, Sandra A. Jablonski and Louis M. Weiner
    Cancer Immunol Res November 1 2014 2 (11) 1103-1112; DOI:10.1158/2326-6066.CIR-14-0103

    Surana and colleagues report that neutralizing IL4 altered the tumor microenvironment (TME) and enhanced the efficacy of the HER2-directed antibody trastuzumab, thus providing a rationale for targeting soluble mediators in the TME to enhance antitumor antibody therapy.

  • Research Articles
    Murine Splenic CD4+ T Cells, Induced by Innate Immune Cell Interactions and Secreted Factors, Develop Antileukemia Cytotoxicity
    Megan E. Nelles, Joshua M. Moreau, Caren L. Furlonger, Alexandra Berger, Jeffrey A. Medin and Christopher J. Paige
    Cancer Immunol Res November 1 2014 2 (11) 1113-1124; DOI:10.1158/2326-6066.CIR-13-0208

    Nelles and colleagues show in a murine model of leukemia that each of the cytokines IL12, IFNγ, and MCP-1 has a role in guiding a cellular cascade of contactdependent cooperation of NKT cells and DCs that leads to activation of CD4+ cytotoxic T cells and elimination of leukemia.

Back to top
PreviousNext
Cancer Immunology Research: 2 (11)
November 2014
Volume 2, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Public/Private Partnership
  • Priority Brief
  • Cancer Immunology Miniatures
  • Research Articles
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Characterization of Murine Syngeneic Tumor Models
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement